Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.43 |
| ▸ | IL2 | P60568 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31689709 | 1.00 | GSK3B (0.51) | GSK3BMAPK1CLK1DYRK1ANPC1 | |
| SCHEMBL22011141 | 0.89 | MAPK1 (0.52) | GSK3BMAPK1CLK1DYRK1AMAP4K1 | |
| SCHEMBL21961937 | 0.87 | MAPK1 (0.51) | GSK3BMAPK1CLK1DYRK1AMAP4K1 | |
| SCHEMBL21961969 | 0.86 | MAPK1 (0.51) | GSK3BMAPK1CLK1DYRK1AMAP4K1 | |
| SCHEMBL21961975 | 0.86 | MAPK1 (0.53) | GSK3BMAPK1CLK1DYRK1AMAP4K1 | |
| SCHEMBL21961944 | 0.85 | SNCA (0.51) | GSK3BMAPK1CLK1DYRK1AMAP4K1 | |
| SCHEMBL21961959 | 0.84 | MAPK1 (0.49) | GSK3BMAPK1CLK1DYRK1AMAP4K1 | |
| SCHEMBL22011270 | 0.84 | MAPK1 (0.57) | GSK3BMAPK1CLK1DYRK1AMAP4K1 | |
| SCHEMBL21961984 | 0.84 | MAPK1 (0.49) | GSK3BMAPK1CLK1DYRK1AMAP4K1 | |
| SCHEMBL31689711 | 0.84 | MAPK1 (0.57) | GSK3BMAPK1CLK1DYRK1AMAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002294-A1 | ERK INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-01-06 | — | — | US | disclosed |
| WO-2020102686-A1 | ERK INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002294-A1 | ERK INHIBITORS AND USES THEREOF | MAPKAPK2, MAPK3, MAP4K2 | GSK3B 358/4885MAPK1 11/4885CLK1 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.